Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype

Next Previous
X
Search
Trial Profile

Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 07 Feb 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; Palbociclib (Primary) ; Ribociclib (Primary)
  • Indications Acute myeloid leukaemia; Astrocytoma; Bone metastases; Brain metastases; Breast cancer; Colorectal cancer; Gastrointestinal stromal tumours; Glioblastoma; Glioma; Malignant melanoma; Mantle-cell lymphoma; Multiple myeloma; Non-small cell lung cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 01 Feb 2024 Status changed from not yet recruiting to withdrawn prior to enrolment because funding was not secured.
    • 15 Jan 2024 Planned End Date changed from 1 Dec 2026 to 1 Mar 2027.
    • 15 Jan 2024 Planned primary completion date changed from 1 Dec 2026 to 1 Mar 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top